

# Eef L Theunissen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5301398/publications.pdf>

Version: 2024-02-01

63  
papers

2,791  
citations

201385

27  
h-index

182168

51  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2315  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. <i>Neuropsychopharmacology</i> , 2006, 31, 2296-2303.	2.8	322
2	Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. <i>Journal of Psychopharmacology</i> , 2009, 23, 266-277.	2.0	294
3	Cognition and motor control as a function of $\Delta^9$ -THC concentration in serum and oral fluid: Limits of impairment. <i>Drug and Alcohol Dependence</i> , 2006, 85, 114-122.	1.6	262
4	Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. <i>Psychopharmacology</i> , 2011, 214, 391-401.	1.5	125
5	Effect of Cannabidiol and $\Delta^9$ -Tetrahydrocannabinol on Driving Performance. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2177.	3.8	106
6	Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint. <i>Journal of Analytical Toxicology</i> , 2008, 32, 470-477.	1.7	98
7	Medicinal $\Delta^9$ -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. <i>Addiction</i> , 2012, 107, 1837-1844.	1.7	91
8	Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT <sub>2</sub> and 5-HT <sub>1</sub> Receptors. <i>PLoS ONE</i> , 2012, 7, e40187.	1.1	77
9	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 215-222.	1.4	73
10	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 461-466.	2.5	71
11	Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. <i>PLoS ONE</i> , 2013, 8, e53127.	1.1	69
12	A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	64
13	Pharmacokinetic Properties of $\Delta^9$ -Tetrahydrocannabinol in Oral Fluid of Occasional and Chronic Users. <i>Journal of Analytical Toxicology</i> , 2010, 34, 216-221.	1.7	62
14	Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. <i>Psychopharmacology</i> , 2012, 220, 341-350.	1.5	62
15	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. <i>European Neuropsychopharmacology</i> , 2020, 41, 81-91.	0.3	62
16	Acute and subchronic effects of bilastine (20 and 40%mg) and hydroxyzine (50%mg) on actual driving performance in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2011, 25, 1517-1523.	2.0	50
17	Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. <i>European Neuropsychopharmacology</i> , 2020, 36, 191-205.	0.3	48
18	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2021, 35, 398-405.	2.0	47

#	ARTICLE	IF	CITATIONS
19	Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. <i>European Neuropsychopharmacology</i> , 2019, 29, 247-256.	0.3	45
20	Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. <i>Human Psychopharmacology</i> , 2007, 22, 289-297.	0.7	40
21	Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 79-86.	1.1	39
22	The why behind the high: determinants of neurocognition during acute cannabis exposure. <i>Nature Reviews Neuroscience</i> , 2021, 22, 439-454.	4.9	36
23	Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH18: a phase 1, placebo-controlled, pilot study. <i>British Journal of Pharmacology</i> , 2018, 175, 18-28.	2.7	34
24	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. <i>Psychopharmacology</i> , 2011, 215, 321-332.	1.5	32
25	Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. <i>Addiction Biology</i> , 2021, 26, e12870.	1.4	31
26	Developmental changes in distinguishing concurrent auditory objects. <i>Cognitive Brain Research</i> , 2003, 16, 210-218.	3.3	30
27	Memory and mood during MDMA intoxication, with and without memantine pretreatment. <i>Neuropharmacology</i> , 2014, 87, 198-205.	2.0	28
28	MDMA, cannabis, and cocaine produce acute dissociative symptoms. <i>Psychiatry Research</i> , 2015, 228, 907-912.	1.7	28
29	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. <i>Psychopharmacology</i> , 2015, 232, 343-353.	1.5	26
30	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 658-666.	2.3	26
31	Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 145-152.	1.9	22
32	Neurocognitive performance following acute mephedrone administration, with and without alcohol. <i>Journal of Psychopharmacology</i> , 2016, 30, 1305-1312.	2.0	22
33	Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication. <i>Addiction Biology</i> , 2017, 22, 823-832.	1.4	22
34	Stimulating Effects of H1-Antagonists. <i>Current Pharmaceutical Design</i> , 2006, 12, 2501-2509.	0.9	21
35	Comparing the Stimulant Effects of the H1-Antagonist Fexofenadine With 2 Psychostimulants, Modafinil and Methylphenidate. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 439-443.	0.7	21
36	Mephedrone and Alcohol Interactions in Humans. <i>Frontiers in Pharmacology</i> , 2019, 10, 1588.	1.6	21

#	ARTICLE	IF	CITATIONS
37	Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. <i>Journal of Psychopharmacology</i> , 2015, 29, 324-334.	2.0	19
38	Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. <i>PLoS ONE</i> , 2016, 11, e0149438.	1.1	19
39	A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance. <i>Journal of Psychopharmacology</i> , 2006, 20, 496-505.	2.0	18
40	Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 51-61.	1.5	18
41	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. <i>Addiction Biology</i> , 2022, 27, e13125.	1.4	18
42	Influence of Ethanol on the Pharmacokinetic Properties of $\Delta^9$ -Tetrahydrocannabinol in Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2013, 37, 152-158.	1.7	17
43	Stimulating effects of the antihistamine fexofenadine: testing the dopamine transporter hypothesis. <i>Psychopharmacology</i> , 2006, 187, 95-102.	1.5	16
44	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation. <i>Drug Testing and Analysis</i> , 2018, 10, 644-650.	1.6	16
45	Emotion recognition during cocaine intoxication. <i>European Neuropsychopharmacology</i> , 2015, 25, 1914-1921.	0.3	15
46	The role of P-glycoprotein in CNS antihistamine effects. <i>Psychopharmacology</i> , 2013, 229, 9-19.	1.5	14
47	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. <i>Frontiers in Pharmacology</i> , 2018, 9, 713.	1.6	14
48	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. <i>Psychopharmacology</i> , 2022, 239, 1251-1261.	1.5	12
49	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 202, 173118.	1.3	11
50	Short-Term Effects of Morning Versus Evening Dose of Hydroxyzine 50 mg on Cognition in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 294-301.	0.7	10
51	Cocaine enhances figural, but impairs verbal $\hat{a}$ flexible $\hat{a}$ ™ divergent thinking. <i>European Neuropsychopharmacology</i> , 2019, 29, 813-824.	0.3	10
52	Binding occurs at early stages of processing in children and adults. <i>NeuroReport</i> , 2001, 12, 1949-1954.	0.6	8
53	Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 150, 162-168.	1.4	8
54	Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. <i>Drug Testing and Analysis</i> , 2019, 11, 1028-1034.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Up in Smoke: Comparability of THC Dosing across Performance Studies. <i>Neuropsychopharmacology</i> , 2006, 31, 2800-2801.	2.8	7
56	Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 113008.	1.4	6
57	Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-fluoroamphetamine intoxication. <i>Human Psychopharmacology</i> , 2018, 33, e2680.	0.7	5
58	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. <i>Analytical Chemistry</i> , 2020, 92, 6065-6071.	3.2	5
59	A single dose of cocaine enhances prospective memory performance. <i>Journal of Psychopharmacology</i> , 2018, 32, 883-892.	2.0	4
60	Analysis of 4-fluoroamphetamine in cerumen after controlled oral application. <i>Drug Testing and Analysis</i> , 2020, 12, 968-974.	1.6	4
61	Phase 1 Clinical Trials in <i>Psychopharmacology</i> . , 2021, , 235-244.		1
62	Reply to: Managing the high: developing legislation and detection methods for cannabis impairment. <i>Nature Reviews Neuroscience</i> , 2021, 22, 585-585.	4.9	0
63	Cannabis Use and Neuroadaptation: A Call for $\delta^9$ -Tetrahydrocannabinol Challenge Studies. <i>Frontiers in Psychiatry</i> , 2022, 13, 870750.	1.3	0